Drug Search Results
More Filters [+]

Chlorotrianisene

Alternative Names: chlorotrianisene, tace
Latest Update: 2024-02-15
Latest Update Note: Clinical Trial Update

Product Description

AstraZeneca is developing TACE (transarterial chemoembolization) as a transarterial therapy procedure for the treatment of hepatocellular carcinoma (HCC). (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03778957)

Mechanisms of Action: ER Modulator

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Injection

FDA Designation: None *

Approval Status: Approved

Approved Countries: Brazil | Chile | Colombia | Dominican Republic | Ecuador | India | Ireland | Ukraine

Approved Indications: None

Known Adverse Events: None

Company: Zhejiang University
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Chlorotrianisene

Countries in Clinic: Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Denmark, Egypt, France, Germany, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Malaysia, Mexico, Netherlands, New Zealand, Norway, Philippines, Portugal, Puerto Rico, Russia, Saudi Arabia, Singapore, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Vietnam

Active Clinical Trial Count: 25

Highest Development Phases

Phase 3: Hepatocellular Carcinoma|Melanoma|Neuroendocrine Tumors|Primitive Neuroectodermal Tumors

Phase 2: Cholangiocarcinoma|Liver Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

JapicCTI-205286

P3

Active

Hepatocellular Carcinoma

2029-12-31

ML42612

P3

Active, not recruiting

Hepatocellular Carcinoma

2029-02-28

35%

ML42612

P3

Active, not recruiting

Hepatocellular Carcinoma

2029-02-28

35%

LEAP-012

P3

Active, not recruiting

Hepatocellular Carcinoma

2028-06-30

44%

LEAP-012

P3

Active, not recruiting

Hepatocellular Carcinoma

2028-06-30

44%

23-OBU-FJ-HCC-II-012

P2

Not yet recruiting

Hepatocellular Carcinoma

2026-11-15

Recent News Events